Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis

Summary

Phase II, single-centre, open label, two parallel arm cohort randomised controlled trial (RCT) testing abatacept in a population of anti-CCP Ab positive individuals at moderate to high risk of developing IA according to a published risk score, already followed in the observational study 'CCP: Next Generation'

Timeline

Start

2020-02-24

Primary completion

2021-03-15

Completion

2021-03-15

Outcome

Outcome not reported

Stopped (Enrollment): “The CI terminated ARCADIA early due to a number of reasons. These include the difficulty in recruiting and being placed on pause during the COVID pandemic, plus limited staffing at that time \& the need to considerably amend the eCRF MACRO system”

Drugs

Indications